ArticleObesity pillars2026
Taking back control: The experience of adults using semaglutide and tirzepatide for obesity treatment - A qualitative study.
Article in Obesity pillars, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Prevalence and Correlates of Perceived Food Noise Among U.S. Adults in a Nationally Representative Sample.Obesity science & practice · 2026Article
- Considering Glucagon-like Peptide-1 Receptor Agonists (GLP-1RAs) for Weight Loss: Insights from a Pragmatic Mixed-Methods Study of Patient Beliefs and Barriers.Healthcare (Basel, Switzerland) · 2026Article
- Patient characteristics and early experiences with anti-obesity medications: the CAMP study.Frontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Adequately treating obesity remains a fundamental goal for improving quality of life and long-term health outcomes. Semaglutide and tirzepatide have shown clinically meaningful weight loss in clinical trials, yet despite this weight loss efficacy, little is understood about how patients with obesity using semaglutide or tirzepatide experience making dietary behavior change. Furthermore, little is known about their perceptions of obesity treatment and healthcare provider interactions since taking the medications. Methods: This was a basic qualitative study wherein adults with obesity taking semaglutide or tirzepatide participated in in-depth interviews and open-ended questionnaires. Participation criteria included a Body Mass Index (BMI) ≥ 30.0 kg/m Results: The final sample included 8 participants (100 % female, mean age 42). Three themes addressed the experience of dietary behavior change: (a) feeling more capable, (b) more measured and deliberate with dietary choices, and (c) experiencing a reduced mental burden. Four themes addressed the experience of obesity treatment: (a) frustration with historical guidance and treatment, (b) hopeful about treatment for the first time, (c) compassion for self and others, and (d) unanticipated outcomes. Finally, two themes addressed the experience of healthcare provider interactions: (a) physicians as gatekeepers to the medications, and (b) physicians were not the initial introduction to the medications. Conclusion: The findings suggest the medications provide a sense of hope for effective treatment, facilitate dietary behavior change, and evoke quality of life benefits beyond weight loss. The patient-provider relationship and obesity knowledge of the physician are integral in discussing and acquiring the medications, yet patients initially learn about the medications outside the healthcare system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.